Spots Global Cancer Trial Database for borderline resectable pancreatic cancer
Every month we try and update this database with for borderline resectable pancreatic cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study | NCT02148549 | Patients With B... | FIRINOX | 20 Years - 74 Years | Wakayama Medical University | |
Divestment for Artery-involved Pancreatic Cancer | NCT03443921 | Pancreatic Canc... Locally Advance... Neoadjuvant The... Borderline Rese... | Artery Divestme... Nab-paclitaxel | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery | NCT00833859 | Pancreatic Neop... | GTX (gemcitabin... stereotactic bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer | NCT02459652 | Pancreatic Canc... | S-1 Radiation Thera... | 20 Years - 75 Years | Japan Adjuvant Study Group of Pancreatic Cancer | |
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | NCT04894643 | Pancreatic Canc... Proton Therapy | Proton Ions Nab-PACLitaxel Gemcitabine Capecitabine Surgical resect... | 18 Years - | EBG MedAustron GmbH | |
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study | NCT02148549 | Patients With B... | FIRINOX | 20 Years - 74 Years | Wakayama Medical University | |
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients | NCT01661088 | Pancreatic Canc... | FOLFIRINOX Intensity-modul... Surgical Explor... | 18 Years - | University of Michigan Rogel Cancer Center | |
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC | NCT04855331 | Borderline Rese... | Laparoscopic pa... Open pancreatod... | 18 Years - 80 Years | Fudan University | |
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | NCT04698915 | SBRT Borderline Rese... Unresectable Pa... | Drug GC4711 Placebo | 18 Years - | Galera Therapeutics, Inc. | |
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | NCT04894643 | Pancreatic Canc... Proton Therapy | Proton Ions Nab-PACLitaxel Gemcitabine Capecitabine Surgical resect... | 18 Years - | EBG MedAustron GmbH | |
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer | NCT03850769 | Borderline Rese... | nab-paclitaxel ... | 18 Years - 70 Years | Peking Union Medical College Hospital | |
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | NCT02717091 | Borderline Rese... | FOLFIRINOX gemcitabine + n... | 20 Years - 75 Years | Nagoya University | |
Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) | NCT06384560 | Borderline Rese... | Pembrolizumab | 18 Years - | Amsterdam UMC, location VUmc | |
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery | NCT00833859 | Pancreatic Neop... | GTX (gemcitabin... stereotactic bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma | NCT05083247 | Pancreatic Neop... Pancreatic Aden... Borderline Rese... | mFOLFIRINOX or ... Isotoxic High-D... Surgery | 18 Years - | Erasme University Hospital |